Inside BENEO’s new pulse plant: pioneering sustainable protein from faba beans
Parry Nutraceuticals, a division of E.I.D Parry, announced that its organic spirulina and chlorella cultivation and processing facility, located in Oonaiyur, Pudukottai District, Tamil Nadu, India, has formally received an Establishment Inspection Report (EIR) after closing of inspection under 21 CFR 20.64(d)(3) by the US FDA. This is pursuant to the successful inspection of the facility carried out by FDA in July 2016 and follow-up satisfactory response submitted by the company.
“We are very proud of the result achieved during the FDA inspection. This success is testament to our ongoing commitment towards our quality systems,” says Muthu Murugappan, Business Head.
Based in Chennai, India, Parry Nutraceuticals is a division of EID Parry India Ltd, and part of the Murugappa Group, with more than 30 years of experience in cultivation and processing of microalgae-based nutraceuticals. This includes organic spirulina, organic chlorella, haematococcus pluvialis and other Phytochemicals.
Parry Nutraceuticals is globally recognized for its product quality and safety, the company states, with its products sold under all major brands across the continents.
According to Murugappan, Parry Nutraceuticals aspires to offer a wider array of value-added products from microalgae in the coming years to meet the latest consumer demands.
“Our new product strategy is one of value addition from our existing ‘greens’ stable, coupled with an entry into newer algal and phytochemical verticals. In this regard, some of the products that we will bring to the market in 2017 include organic chlorella, spirulina granules, CO2 extracted lutein and algal beta-glucan, to name a few. These, along with vegan plant proteins, chlorophyll, phycocyanin and algae omega 3s, are some exciting new areas which are under development,” Murugappan says.